📰 Medication Guide News

Page 10 - Medication Guide News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Medication Guide. Real-time updates on events, politics, business and more.

The Highs and Lows of Bipolar Disorder: One woman's experience with an effective treatment for bipolar depression

October 31, 2023

(BPT) - This is a promotional message sponsored by Intra-Cellular Therapies, Inc.

New York United States Greg Mattingly National Institute Of Mental Health National Comorbidity Survey Replication Cellular Therapies Inc

Source: herald-citizen.com

FDA Approves Interchangeable Biosimilar for Multiple Inflammatory Diseases

October 31, 2023

/PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara...

Sarah Yim Cherie Duvall Jones Nikolay Nikolov Office Of Immunology Wezlana To Amgen Inc Office Of Therapeutic Biologics

Source: prnewswire.com

FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade

October 31, 2023

/PRNewswire/ -- Novartis, a global leader in immuno-dermatology and rheumatology, announced today that the US Food and Drug Administration (FDA) has approved...

United States Marlena Abdinoor Dermatol Venereol Donna Atherton Sloan Simpson Hidradenitis Suppurativa

Source: prnewswire.com

FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis

October 26, 2023

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh™ (mirikizumab-mrkz)...

United States Pbruce Sands Rachel Sorvig Burrillb Crohn Patrik Jonsson Prnewswire Eli Lilly

Source: prnewswire.com

Datopotamab deruxtecan plus IMFINZI® (durvalumab) demonstrated robust and durable tumor responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA Phase Ib/II trial

October 22, 2023

WILMINGTON, Del.--(BUSINESS WIRE)--Oct 22, 2023--

City Of United Kingdom Daiichi Sankyo Jillian Gonzales Peter Schmid Brendan Mcevoy

Source: valdostadailytimes.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Merck's WELIREG® (belzutifan) Significantly Improved Progression-Free Survival and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) | Business

October 21, 2023

RAHWAY, N.J.--(BUSINESS WIRE)--Oct 21, 2023--

United States Hippel Lindau Damini Chokshi Peter Dannenbaum Tonik Choueiri Nancy Kohlberg

Source: valdostadailytimes.com

IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer

October 21, 2023

WILMINGTON, Del.--(BUSINESS WIRE)--Oct 21, 2023--

United States United Kingdom Chelsea Ford Brendan Mcevoy Susan Galbraith Shannonn Westin

Source: joplinglobe.com

UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis

October 18, 2023

FDA approval of ZILBRYSQ® (zilucoplan) has been granted for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-ac...

Bruxelles Capitale Jim Baxter Mjamesf Howard Daphne Teo Eculizumab Soliris Howard Jf Jr

Source: businessinsider.com

UCB : announces U.S. FDA approval of ZILBRYSQ (zilucoplan) for the treatment of adults with generalized myasthenia gravis -October 17, 2023 at 06:04 pm EDT

October 18, 2023

UCB announces U.S. FDA approval of ZILBRYSQ[®] for the treatment of adults with generalized myasthenia gravis FDA approval of ZILBRYSQ® has been granted...

Bruxelles Capitale Howard Jf Jr Iris Loew Friedrich Eculizumab Soliris Daphne Teo Jean Christophe Tellier

Source: marketscreener.com